This week we discuss the new anti-obesity drugs that many have claimed could spell an end to the world’s obesity epidemic. But ESG and diseases are not so straight forward. For example, we include diabetes medication but not obesity medication in our access to healthcare key issue. Why is that? We explore the topic in this week’s episode.

Host: Mike Disabato, MSCI ESG Research

Guest: Namita Nair, MSCI ESG Research